2023 Was a tricky year for the biopharma industry, with several corporations downsizing and restructuring their workforces to remain afloat. There are actually signs of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and everyday living sciences market from the latter part of 2023 and have continued their https://sites.google.com/view/bio-sites/blog